Logo image of CDXS

CODEXIS INC (CDXS) Stock Fundamental Analysis

USA - NASDAQ:CDXS - US1920051067 - Common Stock

2.46 USD
+0.06 (+2.5%)
Last: 9/26/2025, 8:00:02 PM
2.46 USD
0 (0%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

2

CDXS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. CDXS has a bad profitability rating. Also its financial health evaluation is rather negative. CDXS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDXS had negative earnings in the past year.
In the past year CDXS has reported a negative cash flow from operations.
In the past 5 years CDXS always reported negative net income.
In the past 5 years CDXS reported 4 times negative operating cash flow.
CDXS Yearly Net Income VS EBIT VS OCF VS FCFCDXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CDXS's Return On Assets of -47.00% is on the low side compared to the rest of the industry. CDXS is outperformed by 84.21% of its industry peers.
CDXS has a worse Return On Equity (-116.80%) than 82.46% of its industry peers.
Industry RankSector Rank
ROA -47%
ROE -116.8%
ROIC N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
CDXS Yearly ROA, ROE, ROICCDXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

CDXS has a Gross Margin of 77.61%. This is amongst the best in the industry. CDXS outperforms 96.49% of its industry peers.
In the last couple of years the Gross Margin of CDXS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CDXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
CDXS Yearly Profit, Operating, Gross MarginsCDXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDXS has more shares outstanding
CDXS has more shares outstanding than it did 5 years ago.
CDXS has a worse debt/assets ratio than last year.
CDXS Yearly Shares OutstandingCDXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CDXS Yearly Total Debt VS Total AssetsCDXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -4.75, we must say that CDXS is in the distress zone and has some risk of bankruptcy.
CDXS has a Altman-Z score of -4.75. This is amonst the worse of the industry: CDXS underperforms 85.96% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that CDXS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.71, CDXS is doing worse than 75.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z -4.75
ROIC/WACCN/A
WACC10.94%
CDXS Yearly LT Debt VS Equity VS FCFCDXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

CDXS has a Current Ratio of 5.82. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
CDXS has a Current ratio of 5.82. This is in the better half of the industry: CDXS outperforms 78.95% of its industry peers.
CDXS has a Quick Ratio of 5.70. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CDXS (5.70) is better than 82.46% of its industry peers.
Industry RankSector Rank
Current Ratio 5.82
Quick Ratio 5.7
CDXS Yearly Current Assets VS Current LiabilitesCDXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

CDXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.15%, which is quite impressive.
Looking at the last year, CDXS shows a decrease in Revenue. The Revenue has decreased by -6.12% in the last year.
The Revenue has been decreasing by -2.83% on average over the past years.
EPS 1Y (TTM)23.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-6.12%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%92.1%

3.2 Future

The Earnings Per Share is expected to grow by 9.90% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.94% on average over the next years. This is a very strong growth
EPS Next Y25.52%
EPS Next 2Y17.09%
EPS Next 3Y19.61%
EPS Next 5Y9.9%
Revenue Next Year0.58%
Revenue Next 2Y10.61%
Revenue Next 3Y18.98%
Revenue Next 5Y20.94%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CDXS Yearly Revenue VS EstimatesCDXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CDXS Yearly EPS VS EstimatesCDXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDXS Price Earnings VS Forward Price EarningsCDXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDXS Per share dataCDXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CDXS's earnings are expected to grow with 19.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.09%
EPS Next 3Y19.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CODEXIS INC

NASDAQ:CDXS (9/26/2025, 8:00:02 PM)

After market: 2.46 0 (0%)

2.46

+0.06 (+2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners81.16%
Inst Owner Change6.79%
Ins Owners2.18%
Ins Owner Change7.18%
Market Cap222.06M
Analysts81.54
Price Target7.22 (193.5%)
Short Float %5.68%
Short Ratio4.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.73%
Min EPS beat(2)-3.36%
Max EPS beat(2)16.81%
EPS beat(4)1
Avg EPS beat(4)-64.3%
Min EPS beat(4)-251.59%
Max EPS beat(4)16.81%
EPS beat(8)3
Avg EPS beat(8)-36.67%
EPS beat(12)6
Avg EPS beat(12)-18.24%
EPS beat(16)10
Avg EPS beat(16)2.78%
Revenue beat(2)1
Avg Revenue beat(2)-8.47%
Min Revenue beat(2)-23.47%
Max Revenue beat(2)6.53%
Revenue beat(4)2
Avg Revenue beat(4)-7.65%
Min Revenue beat(4)-23.47%
Max Revenue beat(4)9.58%
Revenue beat(8)4
Avg Revenue beat(8)2.4%
Revenue beat(12)6
Avg Revenue beat(12)1.74%
Revenue beat(16)9
Avg Revenue beat(16)4.78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.31%
EPS NY rev (1m)3.16%
EPS NY rev (3m)9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.88
P/FCF N/A
P/OCF N/A
P/B 3.99
P/tB 4.18
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.63
BVpS0.62
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47%
ROE -116.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.61%
FCFM N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.3%
Cap/Sales 11.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.82
Quick Ratio 5.7
Altman-Z -4.75
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)83.6%
Cap/Depr(5y)171.77%
Cap/Sales(3y)6.52%
Cap/Sales(5y)7.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y25.52%
EPS Next 2Y17.09%
EPS Next 3Y19.61%
EPS Next 5Y9.9%
Revenue 1Y (TTM)-6.12%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%92.1%
Revenue Next Year0.58%
Revenue Next 2Y10.61%
Revenue Next 3Y18.98%
Revenue Next 5Y20.94%
EBIT growth 1Y-7.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.36%
EBIT Next 3Y12.55%
EBIT Next 5YN/A
FCF growth 1Y-1020.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9318.15%
OCF growth 3YN/A
OCF growth 5YN/A